1. Scrip
  2. >>Business

Lundbeck Looks For Assets Across Value Chain To Ride Storm

 
• By Mike Ward

While the Danish pharma unveiled its best ever financial results, recently installed ceo Deborah Dunsire confirms to Scrip that the company needs to bolster its pipeline and portfolio with assets in all phases of the value chain.

concept graph brain wave EEG
Lundbeck Maintains Focus On Brain Diseases • Source: Shutterstock

It was not that long after Deborah Dunsire took hold of the reins at Lundbeck Inc. that she knew she had a tough job on her hands. Strategic cost-cutting decisions by the previous ceo Kare Schultz, he left to join Teva Pharmaceutical Industries Ltd., had steadied the ship financially but the impending loss of exclusivity of the company’s best-selling drug, Onfi, the epilepsy treatment, was always going to be a major challenge.

Barely two months into the role and the company revealed at the end of October that its most advanced clinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.